Phase 2 N=120 Safety and Antiviral Activity of BLD-2660 in COVID-19 Hospitalized Subjects
Sars-CoV-2 · Covid19
Primary: Time to Recovery — 5; 4.5 days
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=84 Cx611-0204 SEPCELL Study
Bacterial Pneumonia
Primary: Number of Participants Reporting One or More Treatment-emergent Adverse Events (TEAEs) — 37; 40 Participants
Phase 2 N=59 A POC and Dose-Ranging Study of HTD1801 in PSC Patients
Primary Sclerosing Cholangitis (PSC)
Primary: Absolute Change in Serum Alkaline Phosphatase (ALP) From Baseline to Week 6 in Period 1 — -71; -73; 94 U/L
Phase 2 N=6 A Study to Assess Dystrophin Levels in Participants With Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD) Who Have Been Treated With Ataluren
Duchenne Muscular Dystrophy
Primary: Mean Dystrophin Levels as Measured by Electrochemiluminescence (ECL) — 0.0844; 0.1002; 0.1054 nanograms (ng)/mg
Phase 2 N=160 Down Syndrome Memantine Follow-up Study
Down Syndrome · Intellectual Disability
Primary: Efficacy of the Drug Memantine as Assessed by Change in Score on the California Verbal Learning Test-II (CVLT-II) Short Form Total Free Recall — 3.3; 3.49 score on a…
Phase 2 N=20 A Study to Assess Dystrophin Levels in Participants With Nonsense Mutation Duchenne Muscular Dystrophy (nmDMD)
Duchenne Muscular Dystrophy
Primary: Percent Change From Baseline in Dystrophin Level at Week 40, as Measured by ECL — 6.559 percent change
Phase 2 N=28 Pazopanib Hydrochloride in Treating Patients With Stage IV Kidney Cancer
Clear Cell Renal Cell Carcinoma · Recurrent Renal Cell Cancer · Stage IV Renal Cell Cancer
Primary: Confirmed Response Rate (Complete Response and Partial Response) as Assessed by RECIST 1.1 Criteria — 14; 7; 4 Participants
Phase 2 N=34 Sapanisertib in Treating Patients With Stage IV or Recurrent Lung Cancer
Recurrent Lung Squamous Cell Carcinoma · Stage IV Lung Squamous Cell Carcinoma AJCC v7
Primary: Objective Response Rate (Complete Response [CR] + Partial Response [PR]) — 3; 1; 0; 9 Participants
Phase 2 N=263 Phase 1/2a Dose Escalation Study in Participants With CLL, SLL, or NHL
Follicular Lymphoma (FL/Indolent NHL) · Aggressive NHL (a NHL) · Chronic Lymphocytic Leukemia (CLL) / Small Lymphocytic Lymphoma (SLL)
Primary: Phase 1: Number of Participants With a Dose Limiting Toxicity (DLT) — 0; 0; 0; 0 Participants
Phase 2 N=13 Sapanisertib in Treating Patients With Metastatic or Refractory Pancreatic Neuroendocrine Tumor That Cannot Be Removed by Surgery
Pancreatic Neuroendocrine Tumor G1 · Pancreatic Neuroendocrine Tumor G2 · Refractory Pancreatic Neuroendocrine Carcinoma
Primary: Overall Response Rate — 0 proportion of participants
Phase 2 N=100 Study of CE-224,535 A Twice Daily Pill To Control Rheumatoid Arthritis In Patients Who Have Not Totally Improved With Methotrexate
Arthritis, Rheumatoid
Primary: Percentage of Participants With American College of Rheumatology 20% (ACR20) Response at Week 12 — 33.96; 36.17 Percentage of participants — p=0.591
Phase 2 N=56 A Study of the Efficacy and Safety of ETC-1002 in Participants With Statin Intolerance
Hypercholesterolemia
Primary: Percent Change From Baseline to Week 8 in Calculated Low-Density Lipoprotein-Cholesterol (LDL-C) — -32.0; -3.3 Percent Change — p=<0.0001
Phase 2 N=34 A Study to Assess the Efficacy, Safety and Tolerability of Rozanolixizumab in Subjects With Chronic Inflammatory Demyelinating Polyradiculoneuropathy
Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
Primary: Change From Baseline to Week 13 (Day 85) in Inflammatory Rasch-built Overall Disability Scale (iRODS) Score — 0.234; 0.181 score on a scale (logits)
Phase 2 N=24 Inhaled Nitrous Oxide for Treatment-Resistant Depression: Optimizing Dosing Strategies
Depressive Disorder, Major · Depressive Disorder, Treatment-Resistant
Primary: Change in Depression Symptoms Measured by the Hamilton Depression Rating Scale- 21 Items — -3.0; -3.8; -3.9; -4.0 score on a scale — p=0.55
Phase 2 N=142 A Study to Evaluate Whether Macitentan is an Effective and Safe Treatment for Patients With Heart Failure With Preserved Ejection Fraction and Pulmonary Vascular Disease
Heart Failure With Preserved Ejection Fraction
Primary: Percent of Baseline N-terminal Pro-brain Natriuretic Peptide (NT-proBNP) Assessed at Week 24 — 108.39; 106.27 percentage of baseline NT-proBNP — p=0.7923